Eladocagene exuparvovec

Gene therapy / editing

Approvedregulatory verdict

Evidence outlook

Approved: AADC Deficiency

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Weak signalSingle-arm, accepted for approval (FDA label)

Also approved (1)
EU
  • Patients aged 18 months and older with severe aromatic L-amino acid decarboxylase (AADC) deficiency (marketed as Upstaza; authorised under exceptional circumstances)
Product first approved 2022EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
AADC Deficiency

Competitive landscape

Other AADC (aromatic L-amino acid decarboxylase) drugs

VGN-R09b. Compare all 2 AADC (aromatic L-amino acid decarboxylase) drugs

1 other tracked programme targets this mechanism, none of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Eladocagene Exuparvovec: this drugApprovedGene therapy / editingAADC (aromatic L-amino acid decarboxylase)Weak signalNo reviewed efficacy summary
VGN-R09b
Phase 1/2(overall)
Gene therapy / editingAADC (aromatic L-amino acid decarboxylase)not yet gradedNo reviewed efficacy summary

Upcoming events

No upcoming readouts on record for this asset.